We are live on
!
Find out more
TGI
TRV GP III Portfolio holdings
AUM
$6.14M
1-Year Est. Return
45.44%
This Fund
S&P 500
This Quarter
Est. Return
+24.3%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$791M
AUM Growth
-$374M
(-32%)
Cap. Flow
-$491M
Cap. Flow
% of AUM
-62.12%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
|
+$49.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$439M |
| 2 |
Revolution Medicines
RVMD
|
+$67.3M |
| 3 |
Nurix Therapeutics
NRIX
|
+$34.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$42.1B
| $253M | 32.06% |
5,524,031
-1,500,000
| -21% | -$67.3M |
|
2
Pliant Therapeutics
PLRX
$65M
| $230M | 29.05% |
5,839,160
| – | – |
|
|
3
Nurix Therapeutics
NRIX
$2.62B
| $140M | 17.73% |
4,508,333
-914,216
| -17% | -$34.6M |
|
4
Fulcrum Therapeutics
FULC
$288M
| $70.2M | 8.88% |
5,962,202
| – | – |
|
|
DBTX
5
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $35.7M | 4.51% |
+3,139,685
| New | +$49.3M |
|
|
JNCE
6
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $31.3M | 3.96% |
3,048,780
| – | – |
|
7
Voyager Therapeutics
VYGR
$189M
| $30.1M | 3.81% |
6,391,176
| – | – |
|
|
8
Relay Therapeutics
RLAY
$4.3B
| – | – |
-10,551,115
| Closed | -$439M |
|
Similar funds
TOPU
FWM
SCM
CA
GIP
LCMP
SCM
TA
TRV GP III's Q1 2021 Portfolio in Review
As of Q1 2021, TRV GP III held 8 positions worth $791M, down 32% from $1.16B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
TRV GP III withdrew a net $491M in Q1 2021, closing 1 position and reducing 2 holdings. Its most notable exit was Relay Therapeutics, an estimated $439M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, TRV GP III opened a new position in Decibel Therapeutics, Inc. Common Stock worth $35.7M.
- TRV GP III's largest Q1 2021 buy was Decibel Therapeutics, Inc. Common Stock: 3,139,685 shares worth $35.7M.
- TRV GP III's biggest Q1 2021 reduction was Revolution Medicines, cutting an estimated $67.3M.
- TRV GP III fully exited Relay Therapeutics in Q1 2021, selling an estimated $439M.
- TRV GP III's ten largest holdings make up 100% of its $791M portfolio in Q1 2021.
- TRV GP III opened 1 new position and closed 1 in Q1 2021.
- TRV GP III's portfolio value fell 32% quarter-over-quarter to $791M.
Based on TRV GP III's 13F filing for Q1 2021, filed 12 May 2021.